Luspatercept
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Luspatercept
Jul 21, 2024, 20:39 |
Blog
Matteo Della Porta: The final analysis of the COMMANDS trial comparing Luspatercept vs Epoetin alfa
Matteo Della Porta, Professor of Hematology at Humanitas University and Head of CALR (Center for…
Jun 11, 2024, 03:04 |
Blog
Vijendra Singh: Why I'm skeptical about Imetelstat's use for MDS treatment
Vijendra Singh, Medical oncologist at Karmanos cancer center, shared a post on X/Twitter: ''Why I'm…
Apr 8, 2024, 15:14 |
Blog
Uma Borate: Should luspatercept be used as front-line therapy in RS- low-risk transfusion-dependent MDS?
Uma Borate, Acute Leukemia Translation Lead, Associate Professor at OHSU, shared on X: "Fantastic start…
Oct 25, 2023, 18:33 |
Blog
Uwe Platzbecker: He is a role model for how important patient participation and clinical trials are
Quoting Uwe Platzbecker, Head of Medical Department 1, Hematology and Cellular Therapy at Leipzig University,…
Oct 3, 2023, 17:19 |
Drugs
Talha Badar: The story of Luspatercept!
Talha Badar, Assistant Professor of Oncology at Mayo Clinic Comprehensive Cancer Center, recently tweeted: ''Weekend…
Jun 17, 2023, 15:37 |
Drugs
Super results in transfusion-dependent patients on ruxolitinib - Francesco Passamonti
It was a great honor to present at EHA 2023 on behalf of all investigators…
Jun 14, 2023, 17:42 |
Drugs
A great moment of progress - Amer Zeidan
A great moment of progress (& a personal pride for involvement) in lower risk MDS with…
Jun 1, 2023, 02:37 |
Drugs
Luspatercept: A Transformative Therapy for Transfusion-Dependent Myelodysplastic Syndromes
Luspatercept is a transformative therapy for patients with transfusion-dependent myelodysplastic syndromes (MDS). Esteemed oncologist, Dr.…
All:
8
Posts:
1 - 100
OncoDaily Party and Yvonne Award Photos - Part 1
Michael Douglas: The Untold Story of His Battle Against Cancer
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
EMA Joins FDA: Osimerintib + Chemo Approved for EGFR-Mutated Lung Cancer
Kimryn Rathmell: Principles that have kept me going as a Physician Scientist
Facebook
RSS Feed
Twitter
Linkedin
Youtube